Shattuck Labs’ stock tumbles after Phase 1 SL-325 data release despite analyst upgrades, a Buy consensus rating, and progress in IBD treatment.
Importance Rank:
1
Shattuck Labs’ stock tumbles after Phase 1 SL-325 data release despite analyst upgrades, a Buy consensus rating, and progress in IBD treatment.